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to assume a patient’s perspective may improve patient-caregiver
communications.
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OBJECTIVE: To assess differences in the valuation of eight
schizophrenia-related health states using a multi-attribute utility
instrument (MAU)—the Assessment of Quality of Life Ques-
tionnaire (AQoL), and two scaling techniques: the time trade-off
(TTO) and a visual analogue scale (VAS). METHODS: Eight
schizophrenia-related health state scenarios based on severity of
symptoms were presented to 87 participants from the general
population. Scenarios were: A) “good” function with no move-
ment disorders [extrapyramidal symptoms]; B) “good” function
with movement disorders; C) “poor” function with no move-
ment disorders; D) “poor” function with movement disorders;
E) hospitalised relapse with no movement disorders; F) hospi-
talised relapse with movement disorders; G) post-hospitalisation
with no movement disorders; and H) post-hospitalisation with
movement disorders. Participants were educated about how the
symptoms described in these scenarios could impact on quality
of life and were then asked to value each health state using 
the AQoL, TTO, and a VAS ranging from 0–100. RESULTS:
Mean utility values for all health states ranged from 0.68 to 0.01,
0.80 to 0.53, and 0.74 to 0.17 for the AQoL, TTO and VAS,
respectively. For each instrument or scale there was a trend for
higher utility values to be associated with better outcomes and
lower utility values to be associated with poorer outcomes. 
There were differences between the global results for AQoL,
TTO and VAS [Kruskal-Wallis test (p < 0.001)] and differences
between the utility measures for each health state, except
between TTO and VAS results for health state A (p = 0.655),
and between the AQoL and VAS results for health state G (p =
0.094). CONCLUSION: Utility values varied across health states
and in most cases differed signiﬁcantly between instrument
and/or scale. For schizophrenia, the results from AQoL are most
sensitive to differing symptom severity. However, further
research comparing the different utility instruments is required
in this disease area.
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OBJECTIVE: To assess the relationships between depressive
symptoms and functional outcomes in the treatment of patients
diagnosed with schizophrenia or schizoaffective disorder.
METHODS: This was a post-hoc analysis of a randomized,
double-blind, 24-week study of antipsychotic treatment for
patients diagnosed with schizophrenia or schizoaffective disor-
ders with prominent depressive symptoms (N = 394). Measures
included the SCAP Health Questionnaire (SCAP-HQ) for func-
tional outcomes and the Montgomery-Åsberg Depression Rating
Scale (MADRS) for depressive symptoms. Associations between
depressive symptoms at baseline and functional outcomes at
baseline and at 24-weeks (LOCF) were evaluated controlling for
severity of schizophrenia symptoms (measured with the Positive
and Negative Symptoms Scale (PANSS)) and extrapyramidal
symptoms measured with the Barnes Akathisia Scale, the
Simpson-Angus Scales, and the Abnormal Involuntary Move-
ment Scale (AIMS). RESULTS: At baseline, depressive symptoms
were signiﬁcantly correlated with baseline PANSS Positive Symp-
toms and General Psychopathology (p < 0.001), but not with
Negative Symptoms. At baseline, greater severity of depressive
symptoms signiﬁcantly correlated with a higher likelihood of
baseline violent behaviors, suicidal ideations, suicide attempts,
and substance use; and a decreased likelihood of baseline 
participation in a day treatment program and common leisure 
activities (all p < 0.050). Baseline severity of depressive symp-
toms was signiﬁcantly associated with poorer mental health
functioning, increased likelihood of suicidal ideations and sub-
stance use, and with decreased likelihood of participation in a
day treatment program at endpoint (all p < 0.050). CONCLU-
SIONS: Depressive symptoms in schizophrenia or schizoaffective
disorder are associated with worse functional outcomes, both
concurrently and after 24-weeks of treatment with antipsychotic
medications.
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OBJECTIVES: Prior to use in an international study involving
children and adolescents suffering from schizophrenia or bipolar
disorders, the original 21-item Caregiver Strain Questionnaire
(CGSQ) underwent linguistic validation in 19 languages. The
original scale, which measures the strain of caring for children
with emotional and/or behavioural problems on their caregivers,
was developed in US English. A rigorous methodology was
required to ensure conceptual equivalence and cultural relevance
across different languages. METHODS: The translation process
was conducted by a specialist in each target country using the
following standardized methodology: 1) two forward transla-
tions by professional translators who were native speakers of the
target language and ﬂuent in English; 2) comparison and recon-
ciliation of the translations by the specialist in the target country
and the translators; 3) backward translation by a native English
speaker; 4) comparison of source and backward version; 5)
review by a clinician; and 6) comprehension test on ﬁve parents
of children suffering from schizophrenia or bipolar disorders.
RESULTS: The translation process revealed two types of chal-
lenges: a) the translation of technical terms and b) the transla-
tion of idiomatic expressions. In the ﬁrst case the expression
“negative mental and physical health effects” required a simpli-
ﬁed description in the translations. Similarly, the term “care-
giver”, having no literal equivalent, had to be replaced by the
mention of the actual person providing care. As for translations
of idiomatic expressions, paraphrases were often needed to
convey the intended meaning. CONCLUSIONS: The 19 lan-
guage versions of the CGSQ were established according to a rig-
orous translation methodology. The process aims to ensure
conceptual equivalence across different language versions to
facilitate international comparison and pooling of data. The lin-
guistic validation process as a whole supports the advantage of
integrating international feedback on concepts and wording
before a questionnaire is ﬁnalized.
